ArticleInfection and immunity2003
Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 101 citations in OpenAlex.
- Killer Peptide: an antibody-derived self-assembling peptide bridging antimicrobial and host-defense mechanisms.FEMS microbiology reviews · 2026Review
- Killer Peptide-Containing Polyelectrolytic Nanocomplexes to FightPharmaceutics · 2025Article
- The causes and consequences of trained immunity in myeloid cells.Frontiers in immunology · 2024Review
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Review
- In Vitro and In Vivo Anti-Journal of fungi (Basel, Switzerland) · 2021Article
- Defining trained immunity and its role in health and disease.Nature reviews. Immunology · 2020Review
- Novel Activity of a Synthetic Decapeptide AgainstFrontiers in microbiology · 2018Article
- Article
- AC-1001 H3 CDR peptide induces apoptosis and signs of autophagy in vitro and exhibits antimetastatic activity in a syngeneic melanoma model.FEBS open bio · 2016Article
- The protective role of immunoglobulins in fungal infections and inflammation.Seminars in immunopathology · 2015Review
- Killer behavior within the Candida parapsilosis complex.Folia microbiologica · 2014Article
- Antibodies as an unlimited source of anti-infective, anti-tumour and immunomodulatory peptides.Science progress · 2014Review
- β-Actin-binding complementarity-determining region 2 of variable heavy chain from monoclonal antibody C7 induces apoptosis in several human tumor cells and is protective against metastatic melanoma.The Journal of biological chemistry · 2012Article
- Therapeutic monoclonal antibody for sporotrichosis.Frontiers in microbiology · 2012Article
- Article
- Antibody Peptide based antifungal immunotherapy.Frontiers in microbiology · 2012Article
- Antibody constant region peptides can display immunomodulatory activity through activation of the Dectin-1 signalling pathway.PloS one · 2012Article
- Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells.Translational oncology · 2010Article
- Mimetics of hormetic agents: stress-resistance triggers.Dose-response : a publication of International Hormesis Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptides derived from the sequence of a single-chain, recombinant, antiidiotypic antibody (IdAb; KT-scFv) acting as a functional internal image of a microbicidal, wide-spectrum yeast killer toxin (KT) were synthesized and studied for their antimicrobial activity by using the KT-susceptible Candida albicans as model organism. A decapeptide containing the first three amino acids (SAS) of the light chain CDR1 was selected and optimized by alanine replacement of a single residue. This peptide exerted a strong candidacidal activity in vitro, with a 50% inhibitory concentration of 0.056 microM, and was therefore designated killer peptide (KP). Its activity was neutralized by laminarin, a beta1-3 glucan molecule, but not by pustulan, a beta1-6 glucan molecule. KP also competed with the binding of a KT-like monoclonal IdAb to germinating cells of the fungus. In a rat model of vaginal candidiasis, local, postchallenge administration of KP was efficacious in rapidly abating infections caused by fluconazole-susceptible or -resistant C. albicans strains. In systemic infection of BALB/c or SCID mice preinfected intravenously with a lethal fungal load, KP caused a highly significant prolongation of the median survival time, with >80% of the animals still surviving after >60 days, whereas >90% of control mice died within 3 to 5 days. KP is therefore the first engineered peptide derived from a recombinant IdAb retaining KT microbicidal activity, probably through the interaction with the beta-glucan KT receptor on target microbial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.